[INTERLEUKIN-1Β AND INTERLEUKIN-6 - A NEW MARKERS OF METABOLIC DISORDERS IN DIABETES MELLITUS TYPE 2].
A total of 102 patients with diabetes type 2 and no severe diabetic complications were examined in the endocrinology department of the Kharkiv Regional Clinical Hospital. The following data were analyzed: anthropometric measurements, indicators of carbohydrate and lipid metabolism, the level of activity of pro-inflammatory cytokines interleukin-1β and interleukin-6; as well as the intensity of cardiometabolic disorders, assessed by echocardiography. A statistical analysis revealed an increase of interleukin-1β and interleukin-6 activity, starting from the early stages of the disease, as well as the direct participation of these cytokines in the formation and progression of diabetic dyslipidemia and hyperinsulinemia, which allows us to consider them as the markers of metabolic disorders in patients with diabetes type 2.